Zobrazeno 1 - 10
of 41
pro vyhledávání: ''
Autor:
Lijun Zhang, Shenghui Tang, Richard Pazdur, V. Ellen Maher, James Xu, Rajeshwari Sridhara, Geoffrey Kim, Amna Ibrahim
Publikováno v:
The Oncologist
On November 23, 2015, the U.S. Food and Drug Administration approved nivolumab for patients with advanced renal cell carcinoma who have received prior anti‐angiogenic therapy. The overall benefit/risk profile demonstrated in trial CA209025 supporte
Publikováno v:
The Oncologist
The safety and activity findings of abiraterone acetate plus prednisone treatment in black men with mCRPC were similar to results from previously conducted studies with largely white populations.Poor trial accrual continues to be a challenge in black
Autor:
Grant R. Williams, Tomohiro F. Nishijima, Kirsten A. Nyrop, Allison M. Deal, Hanna K. Sanoff, Hyman B. Muss
Background The decision whether to treat older adults with advanced cancer with standard therapy (ST) or reduced therapy (RT) is complicated by heterogeneity in aging. We assessed the potential utility of the chemotherapy toxicity risk score (CTRS) [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99cc88651b89bafe6bbf67d1c7effe05
https://europepmc.org/articles/PMC5947449/
https://europepmc.org/articles/PMC5947449/
Autor:
Kimberly L. Blackwell, Andriy Krendyukov, Nadja Hoebel, Sreekanth Gattu, Pere Gascón, Nadia Harbeck
Background Evaluation of adverse events (AEs) in pivotal registration trials and ongoing postmarketing surveillance is important for all biologics, including biosimilars. A combined analysis of two pivotal registration studies was performed to streng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0238ac036095c3a4868ed66f147fc65b
https://europepmc.org/articles/PMC5896710/
https://europepmc.org/articles/PMC5896710/
Autor:
Endri Mauro, Simone Ferrero, Michael Mian, Normann Steiner, Patrizia Mondello, Davide Nappi, Claudio Cerchione, Salvatore Cuzzocrea, Wolfgang Willenbacher
Background Rituximab plus bendamustine (R-B) has been demonstrated to improve outcomes and reduce toxicity compared with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma (FL). Nevertheless, in clinical practice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53aae6af5c66b1ef332e84f456cbadad
https://europepmc.org/articles/PMC5896707/
https://europepmc.org/articles/PMC5896707/
Autor:
Ruud van der Noll, Jennifer L. Schutzman, Stephen Leong, Daniel W. Bowles, Jill M. Spoerke, Mark R. Lackner, Joseph A. Ware, Jan H.M. Schellens, Geetha Shankar, Rebecca A. Moss, Jing Zhou, Emile E. Voest
Background Epidermal growth factor receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) are involved in the proliferation and survival of many cancer types. Enhanced antitumor activity may be achieved through combined inhibition of these pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6610d752b31cc50b647cb2cf91547664
https://europepmc.org/articles/PMC5728021/
https://europepmc.org/articles/PMC5728021/
Autor:
Suzanne George, Jason L. Hornick, Karen J. Marcus, Elizabeth H. Baldini, John E. Ready, Thomas F. DeLaney, Francis J. Hornicek, Constance M. Barysauskas, Chandrajit P. Raut, Jennifer Pretz, Yen-Lin Chen, Edwin Choy
BACKGROUND In children with localized Ewing sarcoma (ES), addition of ifosfamide and etoposide to cyclophosphamide, doxorubicin, and vincristine (VDC/IE) improved 5-year overall survival (OS) to 70%-80%. Prior to delivery of VDC/IE in adults, 5-year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51866cd6e57127c6958a7683a23de1d3
https://europepmc.org/articles/PMC5634761/
https://europepmc.org/articles/PMC5634761/
Autor:
Hewei Li, Karijn P M Suijkerbuijk, Christopher D. Lao, David A. Reardon, F. Stephen Hodi, Alexandre Avila, Bartosz Chmielowski, William H. Sharfman, Sergio J Azevedo, James Larkin, Daniel Reshef, Jeffrey S. Weber
Background Despite unprecedented efficacy across multiple tumor types, immune checkpoint inhibitor therapy is associated with a unique and wide spectrum of immune-related adverse events (irAEs), including neurologic events ranging from mild headache
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2f7112be3d6e470186be49f7118afa
https://europepmc.org/articles/PMC5469590/
https://europepmc.org/articles/PMC5469590/
Autor:
Gary Meyer, Deborah Schrag, Jeffrey A. Meyerhardt, Brian M. Wolpin, Charles S. Fuchs, Thomas A. Abrams
Purpose Few population studies have examined patterns of systemic therapy administration in metastatic pancreatic cancer (MPC) or the predictors associated with specific treatment choices. Patients and methods We assessed 4,011 consecutive MPC patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb0230f1955a923a76543ca244077281
https://europepmc.org/articles/PMC5553956/
https://europepmc.org/articles/PMC5553956/
Autor:
Chikamasa Yoshida, Daigo Niiya, Yoshihiro Hatta, Koichi Kitazume, Takaaki Miyake, Masatoshi Kanno, Jun Murakami, Kazuhiko Yamamoto, Masatoshi Uno, Hideki Tsujimura, Yasufumi Masaki, Rika Sakai, Atsuko Hojo, Jun Ozaki, Yoshinobu Maeda, Kazutoshi Aoyama, Jun Takizawa, Katsuhiro Miura, Tomofumi Yano, Jun Konishi, Masanori Makita, Kazutaka Sunami, Yasushi Hiramatsu
Background Decision-making models for elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) are in great demand. Patients and Methods The Society of Lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ea18beefff01a59a3682d6f3c03cd6
https://europepmc.org/articles/PMC5423505/
https://europepmc.org/articles/PMC5423505/